Design and Characterisation of Long-R³-Insulin-Like Growth Factor-I Muteins Which Show Resistance to Pepsin Digestion

References

• Bayne M. L., Applebaum J., Chicchi G. G., Hayes N. S., Green B. G., Cascieri M. A. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor. J. Biol. Chem 1988; 263: 6233–6239
   PubMedGoogle Scholar
• Bayne M. L., Applebaum J., Chicchi G. G., Miller R. E., Cascieri M. A. The roles of tyrosines 24, 31 and 60 in the high affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor. J. Biol. Chem 1990; 265: 15648–15652
   PubMed Web of Science ®Google Scholar
• Bordo D., Argos P. Suggestions for “safe” residue substitutions in site-directed mutagenesis. J. Mol. Biol 1991; 217: 721–729
   PubMed Web of Science ®Google Scholar
• Cascieri M. A., Chicchi G. G., Applebaum J., Green B. G., Hayes N. S., Bayne M. L. Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors. J. Biol. Chem 1989; 264: 2199–2202
   Google Scholar
• Cascieri M. A., Chicchi G. G., Applebaum J., Hayes N. S., Green B. G., Bayne M. L. Biochemistry 1988; 27: 3229–3233
   PubMedGoogle Scholar
• Cascieri M. A., Chicchi G. G., Bayne M. L. Characterisation of the biological activity of IGF I analogs with reduced affinity for the IGF receptors and binding proteins. In Molecular Biology and Physiology of Insulin and Insulin-like Growth Factors, M. K. Raizada, D. LeRoith. Plenum Press, New York 1991; 23–30
   Google Scholar
• Buck M. A., Olah T. A., Weitzmann C. J., Cooperman B. S. Protein estimation by the product of integrated peak area and flow rate. Anal. Biochem 1989; 182: 295–299
   Google Scholar
• Cooke R. M., Harvey T. S., Campbell I. D. Solution structure of human insulin-like growth factor I: A nuclear magnetic resonance and restrained molecular dynamics study. Biochemistry 1991; 30: 5484–5491
   PubMed Web of Science ®Google Scholar
• Daughaday W. H., Mariz I. K., Trivedi B. J. Clin. Endocrinol Metab. 1981; 53: 282–288
   Google Scholar
• Dixon M., Webb E. C. Enzymes2nd ed. Longmans Green & Co Ltd, London 1964
   Google Scholar
• Florence A. T., Jani P. U. Novel oral drug formulations. Their potential in modulating adverse effects. Drug Safety 1994; 10: 233–266
   PubMed Web of Science ®Google Scholar
• Forsberg G., Palm G., Ekebacke A., Josephson S., Hartmanis M. Separation and characterization of modified variants of recombinant human insulin-like growth factor I derived from a fusion protein secreted from. Escherichia coli. Biochem. J 1990; 271: 357–363
   Google Scholar
• Francis G. L., Read L. C., Ballard F. J., Bagley C. J., Upton F. M., Gravestock P. M., Wallace J. C. Purification and partial sequence analysis of insulin-like growth factor-I from bovine colostrum. Biochem. J 1986; 8: 207–213
   Google Scholar
• Francis G. L., Ross M., Ballard F. J., Milner S. J., Senn C., McNeil K. A., Wallace J. C., King R., Wells J. R. E. Novel recombinant fusion protein analogues of insulin-like growth factor (1GF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological activity. J. Mol. Endocrinol 1992; 8: 213–223
   PubMed Web of Science ®Google Scholar
• Hunkapiller M. W., Hewick R. M., Dreyer W. J., Hood L. E. High sensitivity sequencing with a gas phase sequenator. Methods in Enzymol 1983; 91: 399–413
   PubMed Web of Science ®Google Scholar
• Jones J. I., Clemmons D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995; 16: 3–34
   PubMed Web of Science ®Google Scholar
• King R., Wells J. R. E., Krieg P., Snoswell M., Brazier J., Bagley C. J., Wallace J. C., Ballard F. J., Ross M., Francis G. L. Production and characterisation of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. J. Mol. Endocrinol 1992; 8: 29–41
   PubMed Web of Science ®Google Scholar
• McCusker R. H., Cacacho-Hubner C., Clemmons D. R. Identification of the types of insulin-like growth factor binding proteins that are secreted by muscle cells in vitro. J. Biol. Chem 1989; 264: 7795–7800
   PubMedGoogle Scholar
• Oh Y., Muller H. L., Lee D.-Y., Fielder P. J., Rosenfeld R. G. Characterization of the affinities of insulin-like growth factor (IGF) binding proteins 1–4 for IGF-I, IGF-11, IGF-I/ insulin hybrid and IGF-I analogs. Endocrinology 1993; 132: 1337–1344
   PubMed Web of Science ®Google Scholar
• Peters M. A., Lau E. P., Snitman D. L., Van Wyk J. J., Underwood L. E., Russell W. E., Svoboda M. E. Expression of a biologically active analogue of somatomedin-C/insulin-like growth factor I. Gene 1985; 35: 83–89
   Google Scholar
• Ranade V. V. Drug Delivery Systems 5A. Oral drug delivery. J. Clin. Pharmacol 1991; 31: 2–16
   PubMed Web of Science ®Google Scholar
• Read L. C., Tomas F. M., Howarth G. S., Martin A. A., Edson K. J., Gillespie C. M., Owens P. C., Ballard F. J. Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats. J. Endocrinol 1992; 133: 421–432
   PubMed Web of Science ®Google Scholar
• Ross M., Francis G. L., Szabo L., Wallace J. C., Ballard F. J. Insulin-like growth factor (1GF)-binding proteins inhibit the biological activities of IGF-I and IGF-11, but not des(1–3)IGF-I. Biochem. J 1989; 258: 267–272
   PubMed Web of Science ®Google Scholar
• Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning, A Laboratory Manual, C. Nolan, N. Ford, M. Ferguson. Cold Spring Harbour Press, New York 1989
   Google Scholar
• Sato A., Nishimura S., Ohkubo T., Kyoguku Y., Koyama S., Kobayashi M., Yasuda T., Kobayashi Y. Three-dimensional structure of human insulin-like growth factor-I (IGF-1) determined by 1H-NMR and distance geometry. Int. J. Peptide Protein Res 1993; 41: 433–440
   PubMedGoogle Scholar
• Steeb C.-B., Trahair J. F., Tomas F. M., Read L. C. Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats. Am. J. Physiol 1994; 266: G1090–G1098
   PubMed Web of Science ®Google Scholar
• Upton Z., Francis G. L., Ross M., Wallace J. C., Ballard F. J. Production and characterization of recombinant chicken insulin-like growth factor-I from. Escherichia coli. J. Mol. Endocrinol 1992; 9: 83–92
   Google Scholar
• Xian C. J., Shoubridge C. A., Read L. C. Degradation of IGF-I in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein. J. Endocrinol 1995; 146: 215–225
   PubMed Web of Science ®Google Scholar